A three month prospective audit of systemic antifungal therapy was undertaken in a university hospital in the United Kingdom to determine the patterns of usage of systemic antifungal drugs. The case notes of all patients receiving systemic antifungal agents were reviewed daily and the appropriateness of therapy was determined according to standards in the authoritative literature. One hundred and fifteen courses of treatment with antifungal agents for 1481 days were administered to 74 patients. When a patient had received more than one course of antifungals, both the individual courses and the combination of courses, i.e. a regimen, were judged. Antifungal agents were given as an empirical therapy or as prophylaxis in 68% of the courses, with fluconazole and amphotericin B desoxycholate being the agents most frequently used. Therapy was considered unconventional in 26.9% of the courses and 40.5% of the regimens, mainly because either the indication or the duration of treatment did not conform to conventional practice. Improvement in prescribing practices and standards for ongoing audit can only be achieved if a consensus can be reached on how these agents can be used appropriately.
Introduction
In recent years, several new antifungal agents active against systemic mycoses have been developed. The availability of these agents has important implications for patient care. This is particularly true for the azole compounds, a rapidly expanding family of antifungal agents, as well as for the new formulations of amphotericin B (AmB) using liposomes or lipid complexes (AmB-LP) as delivery systems. These new drugs may be less toxic and have a more favourable profile than AmB-desoxycholate and flucytosine (Lopez-Berestein et al., 1989; Meunier, Prentice & Ringden, 1991; Como & Dismukes, 1994) .
The availability of a wider range of less toxic antifungal agents has facilitated a more aggressive approach to the prophylaxis and treatment of fungal infections and may have precipitated the uninformed and inappropriate prescription of these drugs leading to concerns about the emergence of resistant organisms (Warnock et al., 1988; Case et al., 1991; Persons et al., 1991; Wingard et al., 1991) . Several factors may contribute to the inappropriate prescribing of antifungal agents including the absence of strict guidelines for their use, the complexity of the patient population for whom antifungal therapy is most often indicated and the understandable desire of physicians to use the best drugs available. Novelty and the promotional activities of drug manufacturers may also play a role.
Understanding the common prescribing patterns of antifungal compounds is therefore critical in designing future therapeutic strategies.
Medical audit is a systematic process for improving clinical outcome by comparing performance with agreed best practice, identifying variations and suggesting improvements and evaluating their effect. However, standards of best practice are not always easy to establish and, despite an increasing prevalence of fungal infections and a widening experience in their management, clear guidelines have yet to be established for their treatment, the absence of which undoubtedly hampers the assessment of the appropriateness of therapy. To learn more about prescribing practices with a view to improving them, we undertook a three month prospective audit of systemic antifungal usage in the Hammersmith Hospital.
Patients and methods
The Hammersmith Hospital is a 500 bed tertiary care teaching hospital which admits approximately 20,000 patients annually. The hospital has a bone marrow transplant unit and a cancer treatment unit but is not a major centre for AIDS patients. During the study period, there was no restriction on the use of antifungal agents and the systemic antifungal agents routinely used included parenteral amphotericin-desoxycholate (AmB-DC) and liposomal amphotericin (AmB-LP), oral and iv flucytosine, fluconazole and miconazole and oral ketoconazole and itraconazole. All inpatients who were given systemic antifungal agents between 3 August and 3 November 1992 were included in the study. Their clinical notes, drug charts and nursing notes were reviewed on a daily basis and the underlying disease, the reason for initiating therapy, the dosage, means of administration and duration of therapy and any adverse reactions were recorded on data collection sheets. The number of antifungal days was determined by adding up the total number of antifungal agents given on each day of treatment, e.g. two agents given for 10 days would represent 20 antifungal days. All the microbiological investigations requested and the results were obtained directly from the computer database of the Microbiology Department.
The reasons for using antifungal drugs were classified according to Gross, Pichard & Perfect (1987) as the treatment of a defined fungal infection, empirical treatment, or prophylaxis.
Definitions of fungal infection
A defined systemic fungal infection was one in which there was both clinical evidence of blood or tissue infection and a pathogenic fungus had been cultured from a biopsy or other appropriate specimen from the site involved (Goodman et al., 1992) . A proven superficial fungal infection was defined as a clinically apparent infection of the oropharynx, skin, or genitalia that was confirmed by cultures. Any clinically suspected fungal infection, whether systemic or not, that had not been confirmed by culture or histology, was considered a possible fungal infection. The diagnosis of a probable fungal infection was reserved for any haematological patient with neutropenia (granulocyte counts < 1.0 x 10 9 /L) persisting for more than one week and radiographic evidence typical of invasive aspergillosis of the sinuses or lungs.
Types of treatment
The treatment of proven or probable infection was considered specific and that of a possible fungal infection was defined as empirical. Treatment given because a patient was thought to be at risk of developing a fungal infection but where there was neither clinical nor mycological evidence was considered as prophylaxis.
Methods of assessment
Courses' lasting less than 24 h were excluded from the analysis. Antifungal agents given simultaneously comprised a single regimen and were assessed as such except when assessing a course of therapy in which case the use of each drug was assessed independently.
Assessment of specific therapy
The appropriateness of drugs used to treat proven fungal infection was determined jointly by FG and PGW who followed the guidelines published by the Infectious Diseases Society of America, whereby the information obtained on the indication, the agents selected, the dose, timing, route of administration and duration of treatment were evaluated in relation to the current state-of-the-art practices as noted in the authoritative literature (Marr, Moffet & Kunin, 1988) . The use of AmB-LP in haematological patients was evaluated according to the guidelines introduced in the hospital in September 1991 which required a patient to have a proven or probable fungal infection and a deteriorating renal function denned by a serum creatinine > 140 /imol/L that could not be reversed, e.g. by withdrawing another nephrotoxic drug. AmB-LP could also be used as a substitute for the standard preparation to treat any patients who developed renal failure defined by a serum creatinine > 200 ^mol/L. If renal function improved during treatment, an attempt was made to revert to the standard preparation.
Each course of antifungals was classified as conventional if it was given in accordance with the practice recommended in the literature (Bennet, 1990; Carr & Dismukes, 1992; Medical Letter, 1992; Terrel & Hughes, 1992) or, in the case of AmB-LP, in accordance with the hospital's guidelines. Otherwise it was assessed as unconventional. The indication was assessed as conventional for any course of drugs used to treat proven fungal infection as was the use of AmB as the drug of first choice. Treating infections caused by yeasts with either fluconazole or itraconazole was considered conventional, but not their use in treating systemic infections caused by filamentous fungi. For patients with normal renal function 0.3-1.5 mg/kg/day AmB, 50-400 mg/day fluconazole, 50-150 mg/kg/day flucytosine, 100-400 mg/day itraconazole, 600-3600 mg/kg/day parenteral miconazole were all considered conventional dosages. When treating oesophageal candidosis, between five and 14 days' treatment with AmB or between 2-3 weeks' treatment with azole compounds was considered conventional. Treatment of oropharyngeal candidosis for 5-14 days with azole compounds was assessed as conventional as was the treatment of candidaemia without apparent dissemination with either a total dose of 250-1000 mg of AmB or at least 2 weeks' treatment with azole drugs. Treatment of proven fungal infection with either formulation of AmB was to be continued until a combined total dose of 1.5 g AmB had been administered.
Assessment of empirical courses
The indication was assessed as conventional for all immunocompromised patients who were deteriorating clinically or had persistent fever despite treatment with broad spectrum antibiotics, or who had developed signs and symptoms of pulmonary disease, severe oral mucositis or oesophagitis. The use of AmB as the drug of first choice was accepted as conventional in every case but the use of fluconazole or itraconazole was only accepted for treating severe oral mucositis or oesophagitis. The standards for the dose were the same as those used for assessing specific therapy and the duration of therapy was assessed according to how long the clinical indications still applied. The duration of treatment was considered unconventional when it was continued after the granulocyte count had returned to normal.
Assessment of prophylactic courses
Fluconazole given to bone marrow transplant recipients with neutropenia (Goodman et al., 1992) and AmB given as secondary prophylaxis to any patients with neutropenia and a past history of invasive aspergillosis was considered conventional, whereas the use of systemic antifungal agents for any other purpose was deemed unconventional. The standards for the dose were the same as those used for assessing specific therapy and the duration of treatment was considered conventional when it was continued only until the granulocyte count had returned to normal. The course was judged conventional only when each individual assessment was conventional and a regimen was deemed conventional if every course was judged to be conventional and the combination of antifungal agents employed was considered likely to prove effective or to be reasonable according to the literature. Any trial of therapy was considered an unconventional indication unless it was initiated because of lack of response to the usual therapy.
Drug costs
Details of drug expenditure were obtained from the purchasing records of the pharmacy in which the costs were calculated according to the prices charged during the study period.
Results
Seventy-four (1.8%) of the 4,111 patients admitted to the Hammersmith hospital during the three month audit period were given systemic antifungal agents but the proportion of patients treated varied within the hospital with 17 (65%) of the 26 patients in the Bone Marrow Transplant Unit, 52 (27%) of the 192 in the Haematology ward, 10 (6%) of the 165 in the Oncology ward and 17 (1.6%) of the 1,052 in the other Medical wards being given the agents. Patients had been transferred from one ward to another during their stay in hospital but the antifungal treatment they received was judged as a whole.
A total of 115 treatment courses were administered and the drugs used for each indication are illustrated in Table I . Fluconazole was the most frequently employed agent for each indication and, together with AmB-DC, accounted for 95 (83%) of the courses of treatment and for 1318 (89%) of the 1481 antifungal days. Ketoconazole was not given to any patient during the period of audit and itraconazole, flucytosine and miconazole were seldom used. Prophylaxis was given for a total of 322 days, empirical therapy for 729 days and specific therapy for 430 days giving an average of 20.1, 11.8 and 11.6 days respectively. Sixteen courses of prophylaxis were given to 15 patients (as one patient was given two separate courses). The haematology department accounted for 66 (57%) of the courses, 31 of which were administered in the Bone Marrow Transplant Unit (Table II) . Within each department, fluconazole and AmB-DC were the agents most frequently used for each indication. •Four neutropenic patients on prophylaxis subsequently received empiric therapy. '18% (14/74) patients had more than one underlying disease. 'Number of patients 'Number of patients in whom the particular fungus was isolated.
Indications and drugs used
Sixteen courses of prophylaxis antifungal were given to eight patients who were neutropenic, of whom one received two separate courses, to six BMT recipients and to one HIV-positive patient. Fluconazole was the agent most frequently employed (Table II) . Itraconazole was given as secondary prophylaxis to a patient treated for acute leukaemia because of neutropenia and a past history of invasive aspergillosis. Twenty eight courses of empirical therapy were given to patients with fever of uncertain or undefined aetiology, 27 of whom had been given broad spectrum antibiotics previously. Twenty seven courses were given to patients complaining of oral mucositis or oesophagitis. Five courses were given to patients with signs and symptoms of pulmonary disease and two were given to patients with skin erythema. Thirty six courses of fluconazole and 22 courses of AmB-DC were given for empirical therapy accounting for 58 (93%) of the 62 courses and 700 (96%) of the 729 antifungal days, the drugs being used in combination eleven times. Seventeen neutropenic patients were given 31 courses of antifungal agents for empirical therapy for 402 (55%) antifungal days. Twenty-two of these courses were given to neutropenic patients with fever of uncertain or undefined aetiology and AmB-DC was given in 17 treatment courses. A total of 31 courses of empirical therapy was given for 327 antifungal days to 25 non-neutropenic patients, of whom sixteen had malignant tumours. Fluconazole was used in 24 (77%) courses empirically, mainly because of clinical suspicion of mucosal infection (17 courses).
Specific therapy was given to 17 patients with candidiasis and three with mould infections (Table III) for 430 antifungal days. Fourteen courses of AmB were given for 200 (47%) antifungal days. Twelve courses were employed for deep seated mycosis and another two for oral and oesophageal infections. AmB-LP was given for six of the treatment courses. Fluconazole was given in 14 courses accounting for 155 (36%) of the antifungal days. Nine courses of fluconazole were given for oral and oesophageal infections.
Assessment of courses
Overall, antifungal use was considered conventional in 83 (72%) of the courses (Table IV) . Fluconazole was involved in 25 (81%) of the 31 courses considered unconventional. Six (38%) of the prophylactic courses were assessed as conventional. Nine prophylactic courses (56%) were considered unconventional because systemic antifungal agents were given to five patients with chronic leukaemia, to two with aplastic anaemia, and to one patient suffering chronic graft versus host disease and another with acute leukaemia. One course given to a patient with neutropenia undergoing BMT was deemed unconventional because the treatment was continued long after the neutrophil count had returned to normal.
Forty five (73%) evaluable courses of empirical treatment were considered conventional. Of the 16 unconventional courses, seven were given for an unconventional indication, four times for mild, non-specific oral mucositis in non-neutropenic patients, twice for skin erythema, and once for low grade fever in a nonneutropenic patient. In another two cases, fluconazole was given to two patients with signs and symptoms of pulmonary involvement. Six courses were continued after the neutrophil count had returned to normal. In the final case 400 mg/day fluconazole had been given to a patient with endstage renal disease when a lower dose was considered more appropriate.
Thirty-two (87%) of the 37 courses of specific treatment were considered conventional. Of the five courses deemed unconventional, AmB-LP was given to two patients with normal renal function and fluconazole was given to two patients who had mould infections. Another course of specific therapy was assessed as unconventional because fluconazole had only been given for five days to treat oesophageal candidiasis.
Assessment of regimens
Overall, the use of antifungal regimens was considered conventional in 49 (58%) of the 84 regimens (Table V) . In all cases of prophylaxis, a regimen consisted of one agent and six were assessed as unconventional. Twenty eight (58%) of 48 empirical regimens were considered conventional. Nineteen empirical regimens were assessed as unconventional because at least one of the courses was unconventional and the other six because fluconazole and AmB were given together. Among patients with defined infection 15 (75%) of the 20 regimens were considered conventional. Three specific regimens were assessed as unconventional, in one case because at least one of the courses was unconventional and in two cases because fluconazole and AmB had been given in combination.
Adverse reactions
Adverse drug reactions were associated with 24 (75%) of the 32 courses of AmB-DC of which 20 were related to renal toxicity, although renal impairment led to withdrawal of only six courses of the drug. In contrast, mild to moderate hypokalaemia (2.5-3.5 mmol/L) was the only side-effect probably related to treatment with AmB-LP and occurred in two of the 10 courses. Three (5%) courses of treatment with fluconazole led to side effects probably relating to the drug involving two cases of nausea and vomiting and one case of hepatotoxicity with an elevated alanine aminotransferase of 87.5 IU/L.
Cost of drugs
The cost of antifungal therapy during the study period accounted for approximately 20% of the hospital's expenditure of £245,000 on antimicrobial agents and 6% of the total drug budget of £816,666. AmB-LP and fluconazole together accounted for nearly 90% of the total expenditure on antifungal agents (Table VI) . 
Discussion
In this study, antifungal agents were often used in an unconventional manner although this does not necessarily mean that such uses were always inappropriate, as it is difficult to audit the use of antifungal agents when there are no rigid standards against which to compare practice. In a retrospective audit of AmB use carried out in the USA, no attempt was made to determine whether antifungal drugs had been used correctly or incorrectly mainly because of problems associated with the clinical diagnosis of fungal infections and the lack of consensus on doses and duration of treatment for certain infections (Gross et al., 1987) . Consequently, we only attempted to assess whether the antifungal drugs were used according to current accepted clinical practice as reported in the authoritative literature (Bennet, 1990; Carr & Dismukes, 1992; Medical Letter, 1992; Ten-el & Hughes, 1992) . Antifungal agents, particularly fluconazole, were being used mainly for empirical therapy or prophylaxis. It was also interesting to note that, unlike at Duke University Hospital where AmB was used in 70% of the cases in the treatment of documented infections (Gross et al., 1987) , AmB was given more often in the hospital for empirical therapy than for the specific treatment of defined fungal infections. This was not entirely unexpected since empirical antifungal therapy has become conventional practice for managing the febrile, neutropenic patient (Pizzo et al., 1982; EORTC, 1989; Walsh et al., 1991) . However, it was surprising that only half of the empirical courses of antifungal therapy were given to neutropenic patients.
The use of systemic antifungal agents, mainly fluconazole, for prophylaxis for recipients of bone marrow transplantation and neutropenia is also considered as a conventional practice (Goodman et al., 1992) . However, during the audit period, fluconazole was given more often in settings where its efficacy in preventing systemic fungal infection has not yet been proven.
Nearly half of all regimens were assessed as unconventional largely because of the unconventional use of prophylactic regimens. However, a substantial proportion of treatment regimens was also unconventional because fluconazole and AmB were given together, a practice that is considered both unorthodox and controversial (Schaffer & Frick, 1985; Gallis, Drew & Pickard, 1990; Albert, Graybill & Rinaldi, 1991; Anaissie, 1992) .
Overall, fluconazole was the drug most often employed unconventionally and the majority of courses were given to nonneutropenic patients for whom fungal infection was generally not life threatening. Indeed, the most common reason for using systemic antifungal agents, particularly fluconazole, in this population was to treat suspected mucosal infection. This suggests that physicians found it easier to give fluconazole, especially to patients suffering oral mucositis induced by chemotherapy, rather than confirm the suspected diagnosis of oral candidosis which only requires that blastospores, hyphae and pseudohyphae are seen on a direct smear from friable, white curdy lesions characteristic of candidiasis and that a culture yields Candida albicans. Also, permissive uncontrolled use seems to be the fate of any new drug which, like fluconazole, is relatively safe, non-toxic and inexpensive and can be given orally. Only agreed guidelines for use and regular audit will stem this tendency to be profligate.
The inappropriate use of antifungal agents increases the cost of patient care and may diminish its quality. Moreover, with the arrival of the competitive market in health care and ever increasing budgetary constraints, the direct cost of prescribing a course of antifungal treatment inappropriately may mean that any further opportunity for employing more useful alternatives may be forfeited. This can only be prevented by improving prescribing practices and employing effective audit, neither of which can take place until protocols for drug use become available to provide standards against which to measure performance.
